| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Stewart Jeffrey Ryan, EVP, CHIEF COMMERCIAL OFFICER
Received 40,619 shares by exercise or conversion ($4.13M) · Sold 40,619 shares ($11.9M) · Gave 3,450 shares as a gift |
| 09 Nov 2026 | 144 |
| 03 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent ap... |
| 30 Oct 2026 |
8-K: Results of Operations and Financial Condition
NORTH CHICAGO, Ill., October 30, 2026 – AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2026. |
| 23 Oct 2026 |
Form 3: Carethers John, Director
No securities owned |
| 15 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves ... |
| 05 Oct 2026 |
8-K: Results of Operations and Financial Condition
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted. |
| 02 Oct 2026 |
Form 4: Quaggin Susan E, Director
Granted 59 Stock Equivalent Units ($15.4K) |
| 02 Oct 2026 |
Form 4: Rapp Edward J, Director
Granted 129 Stock Equivalent Units ($33.7K) |
| 03 Sep 2026 |
8-K: Regulation FD Disclosure
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases |
| 18 Aug 2026 |
Form 4: Donoghoe Nicholas, EVP, CHIEF BUS/STRAT OFFICER
Received 32,710 shares by exercise or conversion ($2.58M) · Sold 32,710 shares ($8.18M) |
| 18 Aug 2026 |
8-K: Other Events
SUPPLEMENTAL INDENTURE NO. 13, dated as of August 18, 2026 (this “Supplemental Indenture”), by and between ABBVIE INC., a Delaware corporation (the “Company”) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking associat... |
| 14 Aug 2026 | 144 |
| 06 Aug 2026 | 424B5 |
| 05 Aug 2026 |
8-K: Other Events
AbbVie Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC (together, the “Representatives”) and the othe... |
| 05 Aug 2026 | FWP |
| 04 Aug 2026 | 424B5 |
| 03 Aug 2026 | 10-Q |
| 31 Jul 2026 |
8-K: Results of Operations and Financial Condition
NORTH CHICAGO, Ill., July 31, 2026 – AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2026. |
Loading...